• The US reclassifies licensed medical marijuana from Schedule I to Schedule III, easing regulations.
• This change allows for medical marijuana tax deductions and enhances research opportunities.
• Despite this reclassification, marijuana remains illegal at the federal level for recreational use.
• Forty states have legalized some form of medical marijuana, reflecting changing public attitudes.
• The move is considered the most significant advancement in cannabis policy in over 50 years.

The US Department of Justice, directed by Acting Attorney General Todd Blanche, has officially reclassified state-licensed medical marijuana, moving it from Schedule I to Schedule III under the Controlled Substances Act. This change recognizes cannabis as a less dangerous substance, in the same category as medications like ketamine and testosterone, rather than drugs like heroin and LSD, which were previously how cannabis was classified. This action aligns with President Trump's emphasis on increasing access to medical treatments, as stated during his tenure. However, recreational marijuana remains illegal under federal law, according to BBC and Los Angeles Times.

The order also includes provisions that grant medical marijuana operators major tax breaks and streamline the registration process for state-licensed producers and distributors to work with the U.S. Drug Enforcement Administration (DEA). Blanche stated that this "rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information." Critics had long argued that classifying cannabis in the same category as highly addictive drugs led to unnecessary penalties and hindered research, as outlined in reports by South China Morning Post and Al Jazeera.

The decision follows a directive from Trump in December, urging the DOJ to expedite the reclassification process, which had seen limited progress under the previous administration. In addition to granting tax deductions, the modification permits researchers to access state-licensed marijuana for studies, thereby enhancing the scope of medical research into cannabis applications. As Blanche mentioned, this move will facilitate more targeted and rigorous scientific inquiry into marijuana's potential benefits, a sentiment echoed by cannabis industry leaders who view this as a pivotal moment in federal policy, according to Dawn and The Hill.

Despite these advances, the reclassification does not legalize marijuana federally, as concerns over recreational usage and its implications persist. While 40 states have established medical marijuana programs, and about 24 states have legalized its recreational use, marijuana remains a complex and contentious topic on the national level. The cultural shift towards acceptance of cannabis has increased significantly, with substantial public support for legalization, reflecting changing attitudes towards marijuana use across the country, as detailed by Vox and India Times.